Appendix 4C – Q4 FY25 Quarterly Cash Flow Report
Alterity Therapeutics (NASDAQ: ATHE) reported significant progress in Q4 FY25 for its lead drug candidate ATH434 for Multiple System Atrophy (MSA). The company received FDA Fast Track Designation and reported positive data from two Phase 2 clinical trials. The double-blind study showed 48% reduction in disease severity at 50mg dose and 30% at 75mg dose. The open-label trial demonstrated clinical benefits and slowed brain atrophy.
The company maintains a strong financial position with A$40.66M cash balance as of June 30, 2025, after raising A$26.3M through a placement and receiving an A$3.98M R&D tax incentive refund. Operating cash outflows for the quarter were A$2.35M.
Alterity Therapeutics (NASDAQ: ATHE) ha riportato significativi progressi nel quarto trimestre dell'anno fiscale 2025 per il suo principale candidato farmaco ATH434 per l'Atrofia Sistemica Multipla (MSA). L'azienda ha ottenuto la designazione FDA Fast Track e ha presentato dati positivi da due studi clinici di Fase 2. Lo studio in doppio cieco ha mostrato una riduzione del 48% della gravità della malattia con la dose da 50 mg e del 30% con la dose da 75 mg. Lo studio in aperto ha evidenziato benefici clinici e un rallentamento dell'atrofia cerebrale.
L'azienda mantiene una solida posizione finanziaria con un saldo di cassa di 40,66 milioni di dollari australiani al 30 giugno 2025, dopo aver raccolto 26,3 milioni di dollari australiani tramite un collocamento e aver ricevuto un rimborso fiscale per la ricerca e sviluppo di 3,98 milioni di dollari australiani. Le uscite operative di cassa per il trimestre sono state di 2,35 milioni di dollari australiani.
Alterity Therapeutics (NASDAQ: ATHE) informó avances significativos en el cuarto trimestre del año fiscal 2025 para su principal candidato a medicamento ATH434 para Atrofia Sistémica Múltiple (MSA). La compañía recibió la designación FDA Fast Track y reportó datos positivos de dos ensayos clínicos de Fase 2. El estudio doble ciego mostró una reducción del 48% en la gravedad de la enfermedad con la dosis de 50 mg y del 30% con la dosis de 75 mg. El ensayo abierto demostró beneficios clínicos y ralentizó la atrofia cerebral.
La empresa mantiene una sólida posición financiera con un saldo de efectivo de 40,66 millones de dólares australianos al 30 de junio de 2025, tras recaudar 26,3 millones de dólares australianos mediante una colocación y recibir un reembolso fiscal de I+D de 3,98 millones de dólares australianos. Los flujos de efectivo operativos para el trimestre fueron de 2,35 millones de dólares australianos.
Alterity Therapeutics (NASDAQ: ATHE)는 2025 회계연도 4분기에 다계통 위축증(MSA) 치료제 후보인 ATH434에 대해 중요한 진전을 보고했습니다. 회사는 FDA 패스트 트랙 지정을 받았으며 두 건의 2상 임상시험에서 긍정적인 데이터를 발표했습니다. 이중맹검 연구에서는 50mg 투여군에서 질병 중증도가 48% 감소했으며, 75mg 투여군에서는 30% 감소를 보였습니다. 개방형 시험에서는 임상적 이점과 뇌 위축의 지연이 확인되었습니다.
회사는 2025년 6월 30일 기준 4066만 호주 달러 현금 보유고를 유지하고 있으며, 유상증자를 통해 2630만 호주 달러를 조달하고 398만 호주 달러의 연구개발 세금 환급을 받았습니다. 분기 운영 현금 유출은 235만 호주 달러였습니다.
Alterity Therapeutics (NASDAQ : ATHE) a annoncé des progrès significatifs au 4e trimestre de l'exercice 2025 concernant son principal candidat-médicament ATH434 pour l'atrophie multisystémique (MSA). La société a obtenu la désignation FDA Fast Track et a présenté des données positives issues de deux essais cliniques de phase 2. L'étude en double aveugle a montré une réduction de 48 % de la sévérité de la maladie avec une dose de 50 mg et de 30 % avec une dose de 75 mg. L'essai en ouvert a démontré des bénéfices cliniques et un ralentissement de l'atrophie cérébrale.
La société conserve une solide position financière avec un solde de trésorerie de 40,66 millions de dollars australiens au 30 juin 2025, après avoir levé 26,3 millions de dollars australiens via un placement et reçu un remboursement fiscal R&D de 3,98 millions de dollars australiens. Les sorties de trésorerie opérationnelles pour le trimestre se sont élevées à 2,35 millions de dollars australiens.
Alterity Therapeutics (NASDAQ: ATHE) meldete im vierten Quartal des Geschäftsjahres 2025 bedeutende Fortschritte für seinen führenden Arzneimittelkandidaten ATH434 bei Multisystematrophie (MSA). Das Unternehmen erhielt die FDA Fast Track Designation und berichtete positive Daten aus zwei Phase-2-Studien. Die Doppelblindstudie zeigte eine Reduktion der Krankheits-Schwere um 48% bei einer Dosis von 50 mg und 30% bei 75 mg. Die Open-Label-Studie zeigte klinische Vorteile und verlangsamte die Gehirnatrophie.
Das Unternehmen verfügt über eine starke finanzielle Position mit einem Barguthaben von 40,66 Mio. AUD zum 30. Juni 2025, nachdem es durch eine Platzierung 26,3 Mio. AUD eingenommen und eine F&E-Steuerrückerstattung von 3,98 Mio. AUD erhalten hat. Die operativen Cash-Abflüsse im Quartal betrugen 2,35 Mio. AUD.
- None.
- None.
Insights
Alterity's ATH434 shows promising efficacy in MSA trials with FDA Fast Track designation bolstering its regulatory pathway.
Alterity's ATH434 has achieved a significant regulatory milestone with FDA Fast Track designation for Multiple System Atrophy (MSA), complementing its existing Orphan Drug Designation. This accelerated regulatory pathway could substantially compress development timelines for this potential first-in-class treatment for a disease with no approved therapies.
The clinical data package is particularly compelling. In the double-blind Phase 2 trial (ATH434-201), the drug demonstrated a 48% relative treatment effect at the 50mg dose (p=0.02) on the modified UMSARS I scale, which the FDA considers clinically meaningful. Secondary endpoints including the Clinical Global Impression scale and Orthostatic Hypotension assessments showed consistent improvements, with wearable sensor data confirming increased patient mobility.
The open-label Phase 2 trial in more advanced MSA patients further validates ATH434's potential. Progression on UMSARS I was 3.5 points over 12 months versus historical controls showing 6.5 points - representing approximately 46% slowing of functional decline. The consistent efficacy across different patient populations strengthens the drug's profile.
Mechanistically, ATH434 functions as a moderate affinity iron chaperone, addressing a core pathological feature of MSA. The neuroimaging data confirming reduced iron accumulation in affected brain regions (putamen and globus pallidus) provides compelling evidence of target engagement and correlates with observed clinical benefits and reduced brain atrophy.
The favorable safety profile across trials positions ATH434 well for future development, with no serious adverse events attributed to treatment. With A$40.66M cash following a A$26.3M capital raise, Alterity appears well-positioned to advance this promising therapy toward regulatory interactions and potential pivotal trials.
The A$40.66M cash position provides Alterity with a solid operational runway as they advance their lead asset. The quarterly burn rate of A$2.35M suggests approximately 17 quarters of cash at current spending levels, though this will likely accelerate as they move toward potential pivotal trials for ATH434.
The company has successfully strengthened its balance sheet with a A$26.3M capital raise (gross proceeds) completed during the quarter. Additionally, Alterity received A$3.98M from the Australian R&D Tax Incentive Scheme, providing non-dilutive capital to support ongoing research activities.
From a market opportunity perspective, MSA represents a compelling orphan indication with no approved therapies. The clinical data showing consistent efficacy across trial populations positions ATH434 as a potential first-to-market therapy in this high-unmet-need condition.
The FDA Fast Track designation adds significant regulatory value, potentially shortening the time to market through accelerated development pathways including possible rolling review of a New Drug Application, Accelerated Approval and Priority Review eligibility. These regulatory advantages could substantially reduce time-to-market and associated development costs.
The comprehensive clinical data package from both double-blind and open-label trials across different patient populations strengthens Alterity's position for upcoming FDA interactions. With meaningful efficacy signals on endpoints the FDA has acknowledged as clinically meaningful, the regulatory path appears clearer than typical for orphan neurodegenerative diseases.
With strong cash reserves, encouraging clinical data, and enhanced regulatory positioning, Alterity appears well-positioned to advance ATH434 through the next stages of development while maintaining financial flexibility.
Highlights
- Granted U.S. FDA Fast Track Designation for ATH434 to treat Multiple System Atrophy (MSA)
- Reported positive topline data from open-label Phase 2 clinical trial of ATH434 in MSA
- Presented additional analyses from the ATH434-201 trial demonstrating continued robust efficacy for the treatment of MSA
- Cash balance on 30 June 2025 of A
$40.66M
MELBOURNE, Australia and SAN FRANCISCO, July 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 30 June 2025 (Q4 FY25).
“U.S. FDA Fast Track designation for ATH434 in MSA was the highlight of the recent quarter that also featured additional positive clinical data from our Phase 2 double-blind trial,” said David Stamler, M.D., Chief Executive Officer of Alterity. “Receiving Fast Track Designation alongside the Orphan Drug Designation we have already received underscores the promise of this potentially disease modifying therapy to address the urgent needs of individuals with MSA. In addition, we presented additional efficacy data from the ATH434-201 double-blind trial at prominent medical meetings, including slowing of disease progression on the Unified MSA rating scale or UMSARS, improvement in key symptoms of MSA, and preserved activity in the outpatient setting.”
“We were also very pleased to announce positive results from our ATH434-202 open-label Phase 2 clinical trial this week, in which ATH434 demonstrated a clinical benefit on the UMSARS and global assessments of neurological symptoms. Neuroimaging biomarkers showed target engagement and slowed brain atrophy in a manner consistent with the double-blind study findings. Importantly, ATH434 continues to demonstrate a favorable safety profile. These data reinforce our confidence in the MSA program as we prepare for interactions with the U.S. FDA,” concluded Dr. Stamler.
Alterity’s cash position on 30 June 2025 was A
Operational Activities
U.S. FDA Fast Track Designation for ATH434
In May 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ATH434 for the treatment of MSA. This designation is intended to accelerate the development and review of novel investigational products such as ATH434 and recognizes its potential as an innovative approach to address the high unmet need for treating MSA, a disease with no approved therapy. Fast Track designation for a drug candidate confers some or all of the following benefits: opportunities for more frequent and early communication with the FDA throughout the development process; rolling review for the future New Drug Application; and eligibility for Accelerated Approval and Priority Review, if relevant criteria are met.
Fast Track eligibility requires demonstration of the potential for clinically meaningful benefits, which can include the mechanism of action, preclinical studies, or data from patient studies. Alterity’s previous interactions with the FDA indicated that the modified Unified Multiple System Atrophy Rating Scale Part I (UMSARS I)1 scale is considered a clinically meaningful endpoint for MSA. Alterity’s Fast Track application included top-line data from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial which demonstrated efficacy on the modified UMSARS I in addition to preclinical data confirming that ATH434 is a moderate affinity iron chaperone and showed efficacy in animal models of MSA.
ATH434–201: Randomized, Double-Blind, Placebo Controlled Phase 2 Clinical Trial in MSA
In May 2025 additional analyses from the ATH434-201 trial were presented at the International MSA Congress. The presentation, entitled, “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy”, evaluated the clinical analysis population (n=71) who had at least one post-baseline assessment of the key clinical endpoint, the modified UMSARS I activities of daily living scale. On this endpoint, ATH434 demonstrated a clinically significant reduction in disease severity versus placebo, with a
Additional efficacy assessments showed improvement consistent with the UMSARS I findings. The Clinical Global Impression of Severity Scale2 demonstrated improvement compared to placebo at both dose levels, with difference at 50 mg achieving nominal statistical significance (p=0.0088). On the Orthostatic Hypotension Symptom Assessment (a patient reported outcome), on average, placebo patients worsened by approximately 6 points over 52 weeks whereas both ATH434 treatment groups improved over the same period. Baseline differences in disease severity likely explain the different responses in 50 mg and 75 mg treatment groups.
Increased activity in the outpatient setting, as measured by wearable movement sensors, was observed at both dose levels as compared to placebo utilized in the trial, with clinically meaningful improvements in step count, bouts of walking, total walking time, and total standing time. ATH434 was well tolerated with similar adverse event rates compared to placebo and no serious or severe adverse events attributed to ATH434. Regarding neuroimaging data in 61 participants, ATH434 demonstrated target engagement by stabilizing or reducing iron accumulation at both dose levels compared to placebo in MSA affected brain regions. In addition, ATH434 demonstrated trends in reducing brain atrophy at both dose levels compared to placebo. Overall, the study results support continued advancement of ATH434 for the treatment of MSA.
During the period, multiple additional presentations were delivered on the positive results from the ATH434-201 trial:
- April 2025 – American Academy of Neurology (AAN), Title: “Topline Data from a Randomized, Double Blind, Placebo Controlled Phase 2 Study of ATH434 in Multiple System Atrophy”
- April 2025 – American Academy of Neurology (AAN), Title: “Association Between Wearable Sensor Data and Clinical Scores in Individuals with Early-stage Multiple System Atrophy”
- April 2025 – MSA Research Symposium, University College London, Title: “A Randomized, Double Blind, Placebo Controlled Study of ATH434 in MSA”
ATH434–202: Open-label, Biomarker Phase 2 Clinical Trial in Advanced MSA
Subsequent to the period end, on 28 July 2025, Alterity announced positive positive topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with MSA. Ten (10) participants were enrolled and were treated with oral ATH434 75 mg twice daily for 12 months. The study assessed the safety and efficacy of ATH434 treatment on clinical and biomarker endpoints and evaluated a patient population with more advanced disease than was studied in the double-blind Phase 2 trial. The topline data showed that ATH434 conferred a clinical benefit on areas of impairment in MSA and stabilized key biomarkers that underpin the pathology of the disease.
ATH434 demonstrated a benefit on the key clinical endpoint UMSARS I, which increased from baseline to 12 months by 3.5 (4.7) points. These study data compare favorably to historical data in a similar MSA population, where an increase of 6.5 (6.0) points over 12 months was observed.3 Regarding overall neurological symptoms,
The key biomarker endpoint was defined as the change in brain volume from baseline to 12-months, as measured by the MSA Atrophy Index (MSA-AI)7. Neuroimaging outcomes indicate that ATH434 slowed brain atrophy in MSA affected areas when compared to placebo-treated participants in Study 201. Moreover, the effects on brain volume were comparable to those observed in participants in the 75 mg dose group in Study 201. In addition, ATH434 led to lower iron accumulation in the putamen and globus pallidus as compared to placebo treated patients in Study 201, providing further evidence of target engagement. On average, plasma and CSF Neurofilament Light Chain (NfL) levels were stable over the 12-month treatment period.
ATH434 was well-tolerated with a favorable safety profile. No serious adverse events (SAEs) related to ATH434 were reported, and most adverse events were mild to moderate in severity.
bioMUSE Natural History Study
Subsequent to the period end, on 24 July 2025, the Company announced that an innovative neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy (bioMUSE) Natural History Study was featured in the peer-reviewed journal Annals of Clinical and Translational Neurology. The publication, entitled “The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy,” describes how deep learning methods, a form of artificial intelligence, were used to precisely define the neuroanatomy of key brain regions along with development of a novel brain atrophy measure for tracking disease progression in MSA patients over one year. The results were then correlated with clinical measures of disease severity over the same timeframe. Development of the MSA Atrophy Index can enhance the understanding of MSA progression and provide support for using brain atrophy markers for the evaluation of disease-modifying therapies. These tools offer potential applications in diagnosis, staging, and monitoring of disease severity, contributing to more personalized care in MSA.
In May 2025, additional presentations were delivered from bioMUSE at the at the International MSA Congress in May:
- MSA Atrophy Index (MSA-AI): A Quantitative Imaging Marker for Diagnosis and Monitoring of Multiple System Atrophy
- Cutaneous Phosphorylated Alpha-Synuclein Deposition Informs Autonomic Function in Individuals with Early-Stage Multiple System Atrophy
Corporate Activities
During the period, Alterity strengthened its balance sheet with a total of A
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity recently reported positive data for its lead asset, ATH434, in a Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 is also being evaluated in a Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.
References:
1Unified MSA Rating Scale, Part I (historical review) assess activities of daily living. Domains assessed include speech, swallowing, handwriting, cutting food/handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function and bowel function.
2Clinical Global Impression of Severity: a clinician assessment of the total picture of the subject including the impact of the illness on function and level of distress
3 Wenning et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol 2013; 12: 264–74.
4 Clinical Global Impression of Change: a clinician assessment to evaluate overall neurological symptoms as compared to immediately before starting therapy.
5 Patient Global Impression of Change: a patient assessment to evaluate their overall neurological symptoms as compared to immediately before starting therapy.
6 Orthostatic hypotension is a form of low blood pressure that might cause dizziness, lightheadedness or fainting when rising from sitting or lying down. Source: Mayo Clinic.
7 Trujillo et al. The MSA Atrophy Index (MSA-AI): An Imaging Marker for Diagnosis and Clinical Progression in Multiple System Atrophy. Annals of Clinical and Translational Neurology 2025.
^All p-values are uncorrected
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Millie Macdonald
Head of Investor Relations and Business Development
mmacdonald@alteritytherapeutics.com
+61 3 9349 4906
Ana Luiza Harrop
we-aualteritytherapeutics@we-worldwide.com
+61 452 510 255
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.
Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.
Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
